{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:10:22Z","timestamp":1779106222395,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We evaluated satisfaction with use of a segesterone acetate and ethinyl estradiol (0.15\/0.013\u2009mg) contraceptive vaginal system (CVS) among women who had recently used a monthly contraceptive vaginal ring or contraceptive pills. The CVS is a ring-shaped device used in a 21-days-in\/7-days-out regimen for 13 cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We analyzed\n                      <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                      satisfaction responses at cycle 3 and end of study (EOS) from a subset of participants with documented recent use of the monthly ring or daily pills before enrollment in a multinational, phase 3, 13-cycle trial evaluating the CVS. EOS included results from participants who had completed \u226510 cycles. Results were summarized descriptively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 128 recent ring and 219 recent pill users at cycle 3 (of 1033 survey participants), and 92 and 148, respectively, at EOS (of 622 survey participants); overall satisfaction with CVS use was high (\u226590%). At EOS, most ring (89%) and pill (97%) users liked the CVS as much\/better than any previous method. The two most-liked CVS features included ease of use and 1-year duration; the two most disliked features included ring insertion and feeling it coming out. At EOS, \u226588% of both groups reported no concern about using the same CVS for a year, and most (&gt;80%) had recommended it to friends or family members.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The CVS clinical trial participants who were recent ring\/pill users reported high satisfaction and liked it as much\/better than any previously used contraceptive; the CVS may be a good contraceptive option for switchers. Clinical trial registration NCT00263341.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2022.0264","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:38:44Z","timestamp":1685457524000},"page":"808-815","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users"],"prefix":"10.1177","volume":"32","author":[{"given":"Jeffrey T.","family":"Jensen","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn L.","family":"Westhoff","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Columbia University, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita L.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Essential Access Health, Los Angeles, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelli","family":"Graham","sequence":"additional","affiliation":[{"name":"TherapeuticsMD, Boca Raton, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bernick","sequence":"additional","affiliation":[{"name":"TherapeuticsMD, Boca Raton, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.11.003"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2007.06.001"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31821188ad"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181cf45dc"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.07.004"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30265-7"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2019.02.001"},{"key":"e_1_3_5_9_2","unstructured":"Annovera\u00ae (segesterone acetate and ethinyl estradiol vaginal system) Prescribing Information. TherapeuticsMD. Boca Raton FL. 2018."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1426"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(00)00119-7"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2014.05.015"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2019.07.145"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2002.11949333"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(02)00514-0"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S107586"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2017.1336532"},{"key":"e_1_3_5_18_2","volume-title":"21st ed","author":"Hatcher RA","year":"2018","unstructured":"Hatcher RA, , Nelson AL, , Trussell J, et al. Contraceptive Technology. 21st ed. New York, NY: Ayer Company Publishers, Inc.; 2018."}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2022.0264","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:16:16Z","timestamp":1779102976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2022.0264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1089\/jwh.2022.0264"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2022.0264","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}